# IBSA Institut Biochimique SA, Pazzallo, Switzerland – FDA Inspections

Source: https://www.keypedia.com/companies/ibsa-institut-biochimique-sa/b4d0cf36-d7bc-4ea3-851a-9b0efe59255e

> Inspection records and compliance data for IBSA Institut Biochimique SA in Pazzallo. 9 FDA inspections on record, 2 Form 483s, last inspected March 24, 2023.

---

## Details

- Name: IBSA Institut Biochimique SA
- FEI Number: 3002864272
- Business Operations: API/FDF ANALYTICAL TESTING, FDF MANUFACTURE, IN VITRO BIOEQUIVALENCE OR BIOANALYTICAL TESTING, PACK
- Address Line 1: Via Pian Scairolo 49
- City: Pazzallo
- Country Name: Switzerland
- Address: Via Pian Scairolo 49, Pazzallo, Switzerland
- Country: Switzerland

## Related Documents

- [CRL - IBSA Institut Biochimique SA - Unknown Date](https://www.keypedia.com/records/crl/ibsa-institut-biochimique-sa/d101ca50-a8f5-4485-a0a8-613fedc6f16a) — source: FDA, date: Invalid Date
- [FDA Inspection 1201222 - IBSA Institut Biochimique SA - 2023-03-24](https://www.keypedia.com/records/fda_inspections/ibsa-institut-biochimique-sa/f6ac1d98-bfdc-4d34-9f34-e3f7b77dd3fd) — classification: Voluntary Action Indicated (VAI), source: FDA, date: March 24, 2023
- FDA Inspection 1088003 - IBSA Institut Biochimique SA - 2019-03-28 — classification: No Action Indicated (NAI), source: FDA, date: March 28, 2019
- [FDA Inspection 1056552 - IBSA Institut Biochimique SA - 2018-06-22](https://www.keypedia.com/records/fda_inspections/ibsa-institut-biochimique-sa/d4e90c25-3a67-4af9-bf4c-558778c105de) — classification: Voluntary Action Indicated (VAI), source: FDA, date: June 22, 2018
- FDA Inspection 981959 - IBSA Institut Biochimique SA - 2016-07-08 — classification: No Action Indicated (NAI), source: FDA, date: July 8, 2016
- FDA Inspection 938124 - IBSA Institut Biochimique SA - 2015-07-30 — classification: No Action Indicated (NAI), source: FDA, date: July 30, 2015
- FDA Inspection 853655 - IBSA Institut Biochimique SA - 2013-09-27 — classification: No Action Indicated (NAI), source: FDA, date: September 27, 2013
- FDA Inspection 739060 - IBSA Institut Biochimique SA - 2011-07-07 — classification: No Action Indicated (NAI), source: FDA, date: July 7, 2011
- FDA Inspection 667392 - IBSA Institut Biochimique SA - 2010-05-12 — classification: No Action Indicated (NAI), source: FDA, date: May 12, 2010
- FDA Inspection 667323 - IBSA Institut Biochimique SA - 2010-05-06 — classification: No Action Indicated (NAI), source: FDA, date: May 6, 2010

## Related Companies

- [Cadila Pharmaceuticals Limited](https://www.keypedia.com/companies/cadila-pharmaceuticals-limited/ea4ece29-89c9-42f3-9afa-58348dc605b9)
- [Merck Serono S.p.A.](https://www.keypedia.com/companies/merck-serono-spa/052a4b09-0189-4f5c-bdcc-33182a7d3488)
- [Patheon Inc.](https://www.keypedia.com/companies/patheon-inc/76561a83-edb8-4c76-934b-6b2bd5e67949)
- [Lantheus Medical Imaging, Inc.](https://www.keypedia.com/companies/lantheus-medical-imaging-inc/6e9954f9-4df0-41b8-bad7-e8117a91ef76)
- [Fareva Richmond, Inc.](https://www.keypedia.com/companies/fareva-richmond-inc/d42f54e3-2fe8-4501-b6ba-43cd66d2f5cb)
- [Anesta LLC](https://www.keypedia.com/companies/anesta-llc/821f19a7-cabd-47ab-a635-7880a3c5046d)
- [Thymoorgan Pharmazie Gmbh](https://www.keypedia.com/companies/thymoorgan-pharmazie-gmbh/b58b84eb-57d4-4730-8fbb-58632f71023d)
- [Alphapharm Pty, Ltd.](https://www.keypedia.com/companies/alphapharm-pty-ltd/9007b3c5-9b83-4783-b65d-52eb0246708e)
- [AstraZeneca Nijmegen B.V.](https://www.keypedia.com/companies/astrazeneca-nijmegen-bv/29dc14a3-b8e5-4e0a-9399-8d18afc9d686)
- [Watson Pharma Private Limited](https://www.keypedia.com/companies/watson-pharma-private-limited/846d9c2f-be10-415a-b681-5436e078ebfd)

## Related Officers

- [Clarence E. Jones, PhD](https://www.keypedia.com/people/clarence-e-jones-phd/45ad396d-10bc-4b52-8ee2-b3bc1a94c92f)
